Halozyme Therapeutics Inc (NAS:HALO)
$ 61.25 0.27 (0.44%) Market Cap: 7.79 Bil Enterprise Value: 8.58 Bil PE Ratio: 20.28 PB Ratio: 17.21 GF Score: 90/100

Halozyme Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 03:00PM GMT
Release Date Price: $44.63 (+2.39%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - Research Analyst

Well, Good morning, everyone, and thanks for joining us this morning in the 43rd Annual Goldman Sachs Global Healthcare Conference. This morning, I'm pleased to welcome from Halozyme. We've got the CEO, Helen Torley here today. And so maybe with that, we'll just jump right into questions.

Questions & Answers

Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - Research Analyst

First, for those that aren't familiar, could you just provide a brief overview of the HALO business model? I think it's quite unique relative to the rest of the Biotech.

Helen I. Torley
Halozyme Therapeutics, Inc. - President, CEO & Director

Well, let me start by saying thank you for having us here. And Halozyme is a unique biotech company in that we are profitable. If I give you our guidance for the year before we acquired Antares, we project revenues in the range of $530 million to $560 million. That's resulting in operating income of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot